Table 1 The comparison of the clinical and pathologic between survivors and non-survivor groups
Overall | Survivors | Non-survivors | P value | |
|---|---|---|---|---|
Case n (%) | 202 | 108 | 94 | |
Age, years | 68.54 ± 11.02 | 66.81 ± 10.87 | 70.52 ± 13.91 | 0.017 |
Female (%) | 68.3% | 70.4% | 66.0% | 0.546 |
Height, cm | 159.56 ± 7.44 | 159.39 ± 7.69 | 159.76 ± 7.16 | 0.728 |
Weight, kg | 58.31 ± 9.87 | 56.42 ± 8.96 | 59.96 ± 10.36 | 0.011 |
BMI, kg/m2 | 22.87 ± 3.29 | 23.58 ± 3.53 | 22.05 ± 2.80 | 0.001 |
GNRI | 100.08 ± 10.69 | 104.12 ± 9.80 | 95.44 ± 9.78 | < 0.001 |
Hemoglobin mean, g/L | 124.94 ± 17.97 | 127.12 ± 14.43 | 122.43 ± 21.13 | 0.044 |
Serum albumin mean, g/L | 38.30 ± 5.18 | 40.10 ± 4.19 | 36.23 ± 5.44 | < 0.001 |
NLR | 0.112 | |||
< 2.6 | 61.4% | 66.7% | 55.3% | |
≥ 2.6 | 38.6% | 33.3% | 44.7% | |
Serum CA19-9 (U/mL) > 37 | < 0.001 | |||
No | 58.9% | 72.2% | 43.6% | |
Yes | 41.1% | 27.8% | 56.4% | |
Serum CEA level (ng/mL) > 5 | 0.006 | |||
No | 77.5% | 86.0% | 67.5% | |
Yes | 22.5% | 14.0% | 32.5% | |
T (%) | < 0.001 | |||
I–II | 34.9% | 48.0% | 20.9% | |
III–IV | 65.1% | 52.0% | 79.1% | |
Gallstones (%) | 0.077 | |||
No | 39.9% | 46.1% | 33.0% | |
Yes | 60.1% | 53.9% | 67.0% | |
Tumor size (cm) > 3 (%) | 1.000 | |||
No | 53.2% | 53.6% | 52.9% | |
Yes | 46.8% | 46.4% | 47.1% | |
Differentiation of GBC (%) | < 0.001 | |||
Poor/unknown | 37.4% | 24.2% | 52.5% | |
Well/moderate | 62.6% | 75.8% | 47.5% | |
TNM stage (%) | < 0.001 | |||
I–II | 30.5% | 46.2% | 12.8% | |
III–IV | 69;.5 | 53.8% | 87.2% | |
Lymph node metastases (%) | 0.046 | |||
No | 75.3% | 80.8% | 69.2% | |
Yes | 24.7% | 19.2% | 30.8% | |
GNRI | < 0.001 | |||
≥ 98 | 57.4% | 69.8% | 30.2% | |
< 98 | 42.6% | 31.4% | 68.6% |